Oral therapy against rheumatoid arthritis

• April 18, 2024

In Mexico, 3 out of 4 people suffer from rheumatoid arthritis they are women. It is estimated that in Mexico about 14% of the population suffers some rheumatic disease .

The pharmaceutical Pfizer launched a new oral therapy that demonstrates the benefits regarding the reduction of signs and symptoms of the disease, which slows joint damage, inflammation and pain in the affected area.

In accordance with Peter Taylor , doctor in Oxford University , this substance is a revolutionary method that helps patients with rheumatoid arthritis of moderate to severe levels, where significant remission rates are shown in treated patients.

During the Rheumatoid Arthritis Seminar , held in Los Cabos, Baja California, Taylor points out that this molecule, called Tofacitinib, is the first approved treatment for this pathology belonging to a new class called 'Janus Kinasa Inhibitors' (JAK), which are signaling pathways within the cell important in the inflammation related to this autoimmune condition. This molecule is the first DMAR in 10 years.

For Taylor, being a chemical synthesis therapy orally (tablets) the patient gets the great benefit of autonomy and recovery of their quality of life, in addition to reducing the dependence of a third party on their administration, unlike most injectable drugs currently used in Mexico.

According to American College of Rheumatology, inhibitors JAK enzymes (Janus kinase) have efficacy; About 20% of patients achieved remission in the first 6 months of treatment, that is, they had control of the condition to the degree of not having symptoms.

This new molecule recently received authorization from the Federal Commission for the Protection of Health Risks (COFEPRIS) for the treatment of adult patients with rheumatoid arthritis of moderate to severely active that have had an inadequate response to the so-called Disease-Modifying Antirheumatic Drugs (DMARDs).

Video Medicine: Rheumatoid Arthritis Triggered by Poor Oral Hygiene (April 2024).